Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Targeting ESR1 mutation-induced transcriptional addiction in breast cancer with BET inhibition.
Journal: JCI insight
Published: May 27, 2021
Successful treatment of dermato-neuro syndrome with plasmapheresis.
Journal: BMJ case reports
Published: December 30, 2020
Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 16, 2020
Correction to: Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
Journal: Breast cancer research and treatment
Published: March 18, 2020
Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
Journal: Breast cancer research and treatment
Published: October 09, 2019
Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms.
Journal: Cancer research
Published: September 06, 2017
Functional characterization of the G162R and D216H genetic variants of human CYP17A1.
Journal: The Journal of steroid biochemistry and molecular biology
Published: September 01, 2017
The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer.
Journal: Breast cancer research and treatment
Published: March 28, 2016
Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance.
Journal: Molecular oncology
Published: February 06, 2016
Showing 1-10 of 10
Last Updated: 09/26/2026